MedTrace Logo

QLS1410 in Participants With Uncontrolled Hypertension

NCT07489612 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2026-05-22

No results posted yet for this study

Summary

The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure（SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.

Conditions

  • Hypertension (HTN)

Interventions

DRUG

Dose 1 of QLS1410

QLS1410 tablet administered orally, once daily (QD).

DRUG

Dose 2 of QLS1410

QLS1410 tablet administered orally, once daily (QD).

DRUG

Dose 3 of QLS1410

QLS1410 tablet administered orally, once daily (QD).

DRUG

placebo

Matching placebo tablet administered orally, once daily (QD).

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07489612 on ClinicalTrials.gov